The Discounted Cash Flow (DCF) valuation of BioCryst Pharmaceuticals Inc (BCRX) is 20.87 USD. With the latest stock price at 9.21 USD, the upside of BioCryst Pharmaceuticals Inc based on DCF is 126.6%.
Based on the latest price of 9.21 USD and our DCF valuation, BioCryst Pharmaceuticals Inc (BCRX) is a buy. buying BCRX stocks now will result in a potential gain of 126.6%.
| Range | Selected | |
| WACC / Discount Rate | 7.3% - 10.1% | 8.7% |
| Long-term Growth Rate | 1.0% - 3.0% | 2.0% |
| Fair Price | 15.54 - 32.08 | 20.87 |
| Upside | 68.7% - 248.3% | 126.6% |